Articles by Louis Garguilo

71. We Told You We're Different (And The Best) 3/8/2017

    Most service companies regard themselves as different from their competitors. As a result of those differences, they’ll insist they are the best at exceeding their customers’ expectations. In the biotech and pharma industry, our annual CMO Leadership Awards are a way to verify that customers actually share those self-estimations of prowess.

72. Some Straight Talk To CMOs 3/8/2017

    Achaogen’s Tina Larson opens up on the real business needs of sponsors.

73. Outsourcing 2017: Countries, Costs, & Some Concerns 3/8/2017

    A renewed crossing into Asia or U-turn back to Europe and the U.S.? Thoughts of capacity and costs running over filling your head these days? Perhaps some of the following comments from Outsourced Pharma editorial board members will help answer some of the questions you have regarding outsourcing in 2017.

74. Novartis And The Arrival Of The Continuous Manufacturing Facility 2/15/2017

    The journey to implementation of the disruptive technology of continuous manufacturing began in 2005, according to Markus Krumme of Novartis, with a single question on a slide presented to Novartis development and manufacturing executives. “Why don’t we have facilities that can continuously produce materials?” then-CEO Daniel Vasella asked.

75. Three Experiences Power A Non-Profit's Business Approach 1/31/2017

    Jennifer Dent is all business. At a nonprofit organization. She thinks that's exactly how it’s supposed to be. She also shares the enthusiasm of a humanitarian on a mission. Reviewing three experiences in the career of Dent, president of BIO Ventures for Global Health (BVGH), one might think none of this should be the case.

76. Can Pharma Build An Innovation Business Model For CMOs? 12/1/2016

    The trouble is, sponsor-provider relationships in development and manufacturing haven’t been set up to accommodate innovation. While there are exceptions, CMOs were founded less around innovation and more on rigorous controls and process replication.

77. Silicon Valley, Meet BioPharma And Its CMOs (Please) 7/12/2016

    The information technology titans of Silicon Valley (and beyond) should meet up with the BioPharma industry and its subterranean contract development and manufacturing organizations (CMOs). We believe this could alter the topology of drug development and manufacturing. Here’s why, and an offer to assist in the primo incontro.

78. Move Over ADCs: Nanoparticle-Drug Conjugates Are Joining The Cancer Fight 7/1/2016

    Cerulean Pharma’s business plan is, of course, contingent upon further progress in the clinic, but if that happens, the company may just propel us into an era of the independent, commercially successful nanopharmaceutical company.

79. Takeda CEO Mandate Sets Off A Nano Reaction 4/1/2016

    Vincent Ling, senior director for Takeda New Frontier Science, says “While nanotech as applied to medicine is relatively new, and much of it still in the science mode, it’s going to be fascinating to see where it leads us. I have a feeling that we will end up with applications we haven’t dreamed of yet.”

80. The New Leadership Marketing 3/31/2016

    Marketing today centers on the demonstration of active leadership and its promotion. Executive Editor Louis Garguilo describes this as “leadership marketing,” and says it's a step beyond what has become a stagnant “thought leadership.” He also puts value in a name, and thinks large conferences don’t fit this new age.